Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium.

No Thumbnail Available
Authors
Koivula, R. W.
Heggie, A.
Barnett, A.
Cederberg, H.
Hansen, T. H.
Koopman, A. D.
Ridderstråle, M.
Rutters, F.
Vestergaard, H.
Gupta, R.
Journal
Diabetologia
Type
Journal Article
Research Support, Non-U.S. Gov't
Publisher
Springer
Rights
Archived with thanks to Diabetologia
The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT.
Citation
Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. 2014, 57 (6):1132-42 Diabetologia
Note
This article is freely available via Open Access. Click on the 'Additional Link' above to access the full-text via the publisher's site.